论文部分内容阅读
中药在国际医药贸易中占有一定位置,中国每年出口中药及中成药、中药保健品达160亿美元,约占世界植物药市场份额的5％左右,真正作为“治疗药品”相对较少,仅6亿美元左右。近些年来,化学合成药品药源性疾病不良反应日益增多,国际社会呼吁回归大自然,崇尚天然产品、绿色产品。全世界逐渐形成“中医中药热”。中国医药市场在加入WTO后,将直接面临激烈竞争,原有传统中药产业的产品、管理和科技水平显然与国际医药主流市场的标准和要求仍存在较大差距。同时日本、韩国、印度、泰国,以及一些西方国家应用高科技研究和开发传统医药对我国中药形成巨大威胁,因而中医药所面临的国际挑战十分严峻。
The traditional Chinese medicine occupies a certain position in the international pharmaceutical trade. China exports 16 billion US dollars of traditional Chinese medicines and Chinese patent medicines and Chinese medicine health products each year, accounting for about 5% of the world’s market share of herbal medicines. It is relatively rare as “therapeutic drugs”, only 6 Billion dollars or so. In recent years, the adverse reactions of drug-derived diseases caused by chemical synthesis have increased. The international community has called for returning to nature and advocating natural products and green products. The world has gradually formed “Chinese herbal medicine fever.” After China’s accession to the WTO, China’s pharmaceutical market will face fierce competition. The original traditional Chinese medicine industry’s products, management, and scientific and technological level are obviously still far behind the standards and requirements of the international pharmaceutical mainstream market. At the same time, Japan, South Korea, India, Thailand, and some western countries have applied high-tech research and developed traditional medicine to form a great threat to Chinese medicine, and therefore the international challenges faced by Chinese medicine are very severe.